Reata Pharmaceuticals Inc

Reata Pharmaceuticals — Technical Presentation (May 2018)

5 slides from Reata Pharmaceuticals's technical presentation, May 25, 2018

  1. Slide 1: Slide 1

  2. Slide 2: Initial Results of Bardoxolone Methyl in Polycystic Kidney Disease

    Initial Resu PY Y | of Bardoxo @ @ Polycystic | eee Pablo E. Pergola, Melanie Chin, Ph REATA. Anjay Rastogi, MI BACKGROUND AND PRECLINICA Common pathway of inflammation links diverse etiologies of ¢ Chronic kidney diseases (CKD) develop due to multiple pathogenic proces: disruption of structure, and

  3. Slide 3: Bardoxolone methyl and close analogs improve kidney function in multiple preclinical models

    Baraoxolone methy! (BARD) and close analogs improve kidne fibrosis in multiple preclinical models ¢ Through induction of Nrf2 and suppression of NF-kB, BARD targets pro-inf that contribute to GFR loss in CKD* ¢ BARD and close structural analogs improve kidney function and reduce rer models of CKD an

  4. Slide 4: Efficacy, safety and conclusions

    3 f ate eh Oo N 1 ! Mean + SE eGFR Change (ml/min/1.73 m2) 8 4 6 at 4 as 2 4 -®ADPKD -&IgAN 0 1 1 0 4 8 12 Study Week SAFETY: BLOOD PRESSURE, B Systolic BP Diastolic BP 70 60 Mean + SD DBP (mmHg) © Oo -=ADPKD -eIgAN -*ADPKD -*IgAN 80 T T T 40 r r 1 0 4 8 12 0 4 8 a2 Study Week Study Week CONCLUSIONS

  5. Slide 5: Initial Bardoxolone Results: PHOENIX Phase 2 safety and efficacy

    InitialBardoxolone CKD adverse (2008) Results Cisplatin-Induced eventsfrom The methyl PHOENIX a Phase Acute was 2 Trial Phase generally Kidney of 2the trial Injury; well-tolerated Safety (NCT03366337) Aleksunes, and Efficacy andJPET significantly was of Bardoxolone (2010) initiated Cohort increased

Reata Pharmaceuticals — Technical Presentation (May 2018) on 6ix